CBC parameters and other clinical features stratified according to STAT3 and TET2 mutation. Patients are divided into 4 categories, nonmutant (WT) (n = 29), STAT3 mutant-only (n = 12), TET2 mutant-only (n = 9), and comutation (Co-Mut) of both STAT3 and TET2 (n = 8). Platelets (Welch’s 1-way ANOVA global, P = .0071; Games-Howell post hoc test, WT vs TET2, P = .0074) (A) and relationship between platelet count and mean platelet volume (MPV) (B) in CBC reports from the date closest to the sequencing sample. (C) Overall survival within each group for those patients who have achieved 60 months of follow-up. (D) Need for immunosuppressive treatment within each group for those patients who have achieved 60 months of follow-up. (E) Response to immunosuppressive treatment initiated at any point during disease course (STAT3 vs TET2, Fisher’s exact test, P = .0046). (F) Distribution of patient sex within mutation groups. CR, complete response; F, female; M, male; NR, no response; PR, partial response.